Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress
Grill, Joshua D., RAMAN, REMA , Wang, Shunran , Ernström, Karin , Bhangu, Jaspreet , Dhadda, Shobha , Irizarry, Michael, Lenio, Steven, MacDonald, Steven, Ramanan, Vijay K., Rosenberg, Paul B., Weisman, David, Aisen, Paul, Sperling, Reisa, Sultzer, David L. , Karlawish, Jason , Grill, Joshua D. , Andrews, Patricia , Appleby, Brian S. , Irizarry, Michael C. , Johnson, Keith A. , Lenio, Steven , MacDonald, Steven , Ramanan, Vijay K. , Rosenberg, Paul B. , Aisen, Paul , Sperling, Reisa Anne

Mayo Clinic

JAMA Network Open | March 30, 2026 | Volume: 9 | Issue: 3 | Pages: e263845

10.1001/jamanetworkopen.2026.3845 | PMID 41910973 Get It

Importance Alzheimer disease (AD) biomarker and genetic testing results are increasingly disclosed to cognitively unimpaired adults in research and could in the future inform clinical treatment decisions in this population. Objectives To assess psychological outcomes after returning 3 categories of amyloid biomarker results as well as apolipoprotein E ( APOE ) genotypes. Design, Setting, and Participants This cohort study was a secondary analysis of data collected as part of screening for the multisite AHEAD preclinical AD trial. Participants were individuals aged 55 to 80 years undergoing screening from July 14, 2020, to October 15, 2024. Exposure Participants were informed whether they had not-detected, intermediate, or elevated amyloid positron emission tomography levels, as well as their APOE genotype, which were categorized as noncarrier, ε4 heterozygote, or ε4 homozygote. Main outcomes and measures Impact of Events Scale (IES; 15 items to assess intrusive thoughts and avoidance; each item is scored as not at all [0], rarely [1], sometimes [3], or often [5]; total range, 0-75), collected 24 to 72 hours after disclosure, and change in a scale measuring concerns about AD dementia (adapted scale using 6 items in which participants indicated their level of agreement with statements related to their perceived probability of developing AD dementia; items scored as strongly disagree [1] through strongly agree [5]; total range, 6-30), calculated by subtracting the score collected before biomarker testing from 1 collected after biomarker and genetic test results disclosure. Results Among 3414 included individuals, the mean (SD) age was 68.8 (6.0) years and 2116 (62%) were female. Group mean IES scores were below clinically significant thresholds. Nevertheless, across genetic groups, learning an elevated amyloid result (1184 participants) was associated with higher IES (mean [SD], 10.5 [10.9]) than intermediate amyloid (482 participants; mean [SD] IES, 8.8 [9.8]), and intermediate amyloid was associated with higher scores than not-detected amyloid (1748 participants; mean [SD] IES, 6.5 [8.4]). Across amyloid groups, learning APOE ε4 homozygosity (337 participants) was associated with higher mean (SD) IES (12.7 [11.6]) than heterozygosity (1609 participants; 9.1 [10.2]), and heterozygosity was associated with higher IES than noncarrier status (1468 participants; mean [SD] IES, 6.2 [8.1]). Both types of information were significant in an analysis of covariance model; no interaction effect was observed. In contrast, only biomarker disclosure was associated with differential change in concerns about AD dementia. Those with elevated amyloid showed a mean (SD) increase in concern (0.8 [3.5]), those with intermediate amyloid showed a smaller increase (0.4 [3.7]), and those with not-detected amyloid showed decreased concerns (−1.1 [4.2]). Conclusions and Relevance In this cohort study of cognitively unimpaired adults, associations with intrusive thoughts were observed to differ among genetic and biomarker subgroups; such associations were limited to biomarker subgroups for measures of perceived dementia risk.
A pilot study on AI-based voice analysis for monitoring patients hospitalized with acute decompensated heart failure
Riehle, Leonhard , Fouad, Mariam , Hott, Marcus, Heil, Emanuel , Lee, Chong Bin, Schoenrath, F., Vungarala, Soumya , Johnson, Bruce, Olson, L. J., Goetz, A, Hindricks, Gerhard, Hohendanner, Felix , Schoenrath, Felix , Olson, Lyle, Barata, Filipe , Cummins, Nicholas , Hindricks, Gerhard , Hohendanner, Felix , Hott, Marcus, Lee, Chong Bin , Goetz, Aurèle

Mayo Clinic

European Heart Journal - Digital Health | March 27, 2026 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/ehjdh/ztag052 | PMID 42396380 Get It

Abstract Aims Monitoring pulmonary congestion in chronic heart failure (HF) reduces decompensation and hospitalization, but conventional methods such as weight and symptom tracking are often unreliable. As fluid accumulation affects the lungs and vocal tract, subtle voice alterations may serve as a non-invasive signal for early detection of worsening HF. Methods and results The Voice Analysis for Monitoring Patients with HF trial (VAMP-HF, NCT06566911) prospectively enrolled 104 patients hospitalized with acute decompensated HF (ADHF) across two academic centres in the USA and Germany. Daily voice recordings were collected from admission to discharge, with breathing features extracted from speech and acoustic features from sustained vowels. A machine-learning model was trained to classify recordings as admission-phase vs. discharge-phase using leave-one-patient-out. Patients with clinical deterioration, insufficient audio quality, or short length of stay were excluded. Seventy-nine patients were included in the final dataset. The model classified admission and discharge with an F1-score of 0.83 (95% CI: 0.77–0.90; AUC = 0.90). In patients with higher audio volume (N = 54), performance reached 0.89 (95% CI: 0.82–0.94; AUC = 0.91). When applied to intermediate hospitalization days, model-predicted scores showed progressive increases from admission towards discharge. Performance remained robust irrespective of significant weight loss during hospitalization. Conclusion In this pilot study, structured voice and breathing analysis discriminated hospitalization phase from admission through discharge in patients with ADHF. This non-invasive approach captured progressive changes during the hospital course and warrants further investigation with concurrent objective congestion markers to establish physiological specificity.
AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results From the Multicenter STOMP2 Trial
Schwartz, David A., Dozois, Eric J. , Ehman, Eric C. , Faubion, W, Hudesman, David, Pabla, Baldeep , Papadakis, K, Fleshner, Phillip, Dozois, Eric, Ehman, Eric , Faubion, William , Papadakis, Konstantinos , Schwartz, David A. , Hudesman, D, Johnson, Todd , Fleshner, Phillip

Mayo Clinic

American Journal of Gastroenterology | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004005 | PMID 41879234 Get It

INTRODUCTION: Advanced therapies infrequently achieve complete fistula closure in patients with Crohn's disease (CD). The primary objective of the STOMP2 clinical trial was to determine whether the implantable autologous cell therapy AVB-114 is effective in inducing remission of persistent Crohn's perianal fistulas versus standard of care. METHODS: Eligible patients had a single perianal fistula tract and had failed previous treatment or had documented medication intolerance to biologic or conventional CD therapy. All enrolled subjects underwent surgical fistula optimization and adipose tissue biopsy collection (to manufacture AVB-114) followed by 1:1 randomization to either standard of care (repeat fistula optimization including seton replacement) or AVB-114 implantation. The primary end point was combined fistula remission at 36 weeks, defined as closure of the external opening, no drainage of fluid despite gentle finger compression, and no collections >2 cm in at least 2 of the 3 dimensions on MRI. RESULTS: Subjects at 14 US sites were equally randomized to SoC (N = 24) or AVB-114 (N = 24). Week 36 combined remission was 8.3% and 45.8% for subjects randomized to SoC and AVB-114, respectively (38% difference, 95% CI 11%–60%; P = 0.0078). At week 36, MRI revealed no subjects with collections >2 cm, radiological improvement (≥50% decrease in the Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease (MAGNIFI-CD) score from baseline) in 1 SoC subject and 3 AVB-114 subjects, and radiological healing (complete resolution of T2-weighted hyperintensity in fistula tract) in 2 SoC subjects and 5 AVB-114 subjects. Through week 36, there were 40 and 56 treatment emergent adverse events for SoC and AVB-114, respectively. There were no serious treatment emergent adverse events in the AVB-114 group through week 36. DISCUSSION: A significantly higher proportion of patients treated with AVB-114 achieved combined remission vs SoC, and the treatment was well tolerated. These data support the safety and efficacy of AVB-114 in persistent Crohn's perianal fistulas.
585: EFFECT OF CYSTATIN C ON INITIAL BIVALIRUDIN DOSE SELECTION IN ACUTELY ILL PATIENTS
Wieruszewski, Patrick, Eder, Ty, Johnson, Evan, Cole, Kristin, Barreto, Jasón, Hernandez, Brandy, Kashani, Kianoush, Rule, Andrew, Barreto, Erin, Wieruszewski, Patrick M. , Eder, Ty H., Johnson, Evan, Rule, Andrew D. , Frazee, Erin N.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001184336.18728.fe Get It

437: ALTERNATING HYPEROSMOLAR THERAPY IN PATIENTS WITH ELEVATED AND REFRACTORY INTRACRANIAL PRESSURE
Johnson, M.R. , Brown, Caitlin, Rabinstein, Alejandro, Hawkes, Maximiliano, Cole, Kristin, Vollmer, Nicholas, Johnson, Madelyn, Rabinstein, Alejandro A. , Hawkes, Maximiliano A.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001183744.35546.6e Get It

Abstract A016: Myeloid Hv1-STING axis tunes glioma immunity
Zheng, Jiaying, Zhao, Shunyi, Wang, Meijie , Pallegar, Praveen N., Liu, Langni , Wan, Yushan, Xie, Manling, Beyder, Arthur, Johnson, Aaron J., Wu, Long-jun, Wang, Lingxiao, Ayasoufi, Katayoun , Strege, Peter R. , Zhang, Wen , Goddery, Emma N. , Beyder, Arthur , Johnson, Aaron J.

Mayo Clinic

Cancer Research | March 23, 2026 | Volume: 86 | Issue: 6_Supplement | Pages: A016-A016

10.1158/1538-7445.brain26-a016 Get It

Abstract In many cancers, a major barrier to effective immunotherapy is the dominance of tumor-associated myeloid cells (TAMs), which establish a profoundly immunosuppressive tumor microenvironment (TME). This challenge is particularly pronounced in glioblastoma (GBM), where myeloid cells represent the predominant immune population and actively suppress antitumor immunity. Identifying targets that can reprogram TAMs from an immunosuppressive state toward a pro-inflammatory, antigen-presenting phenotype remains a critical unmet need. Here, we identify the voltage-gated proton channel Hv1 as an immune-restricted regulator of glioma-associated macrophage function. Hv1 is notable not only for its immune-specific expression but also for its established roles in central nervous system (CNS) pathologies, where Hv1 depletion alters microglial and macrophage polarization, reduces myeloid accumulation, dampens inflammatory cytokine production, and limits secondary tissue damage. However, Hv1’s role in shaping the GBM immune landscape—particularly in vivo—has remained poorly understood due to low Hvcn1 transcript abundance and the lack of reliable antibodies and genetic tools. Given the dominance of myeloid cells in GBM and their central role in tumor immune regulation, we sought to define Hv1 function within this highly immunosuppressive brain TME. Analysis of patient datasets revealed that elevated Hv1 expression correlates with poor clinical prognosis. Consistently, Hv1 loss significantly prolonged survival in multiple murine glioma models. Using in vivo two-photon imaging and spectral flow cytometry, we show that Hv1 depletion reprograms TAMs toward an anti-tumor phenotype characterized by enhanced tumor cell phagocytosis, improved antigen presentation, and increased T cell infiltration. By generating new Hv1 reporter and conditional mouse lines, we further demonstrate that tumor-associated microglia and infiltrating macrophages are the principal sources of Hv1 and markedly upregulate its expression in response to glioma. Notably, selective deletion of Hv1 in infiltrating macrophages phenocopied the survival benefit observed with global Hv1 loss. Mechanistically, using mass spectrometry and genetic models, we identify the Stimulator of Interferon Genes (STING) as a previously unrecognized binding partner of Hv1, placing Hv1 within the STING signaling pathway, a central regulator of innate and adaptive immune responses. Together, these findings fill a critical gap in understanding myeloid Hv1 function in GBM and identify Hv1 as a promising target for reprogramming the tumor immune microenvironment. Citation Format: Jiaying Zheng, Lingxiao Wang, Shunyi Zhao, Katayoun Ayasoufi, Meijie Wang, Praveen N. Pallegar, Peter R. Strege, Langni Liu, Yushan Wan, Wenjing Zhang, Emma N. Goddery, Manling Xie, Arthur Beyder, Aaron J. Johnson, Long-Jun Wu. Myeloid Hv1-STING axis tunes glioma immunity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Brain Cancer; 2026 Mar 23-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(6_Suppl):Abstract nr A016.
Association of Overactive Bladder With Fall Risk Among US Adults Aged 20−69 Years
Miller, Larry S., Bhattacharyya, Samir, Noblett, Karen , Turner, Erin, Copeland, Shelley, Ketchandji, Melanie, Linder, Brian J , Miller, Larry E , Noblett, Karen L , Linder, Brian J. , Bhattacharyya, Samir, Turner, Erin

Mayo Clinic

Neurourology and Urodynamics | March 20, 2026 | Volume: 45 | Issue: 4 | Pages: 738-745

10.1002/nau.70270 | PMID 41858015 Get It

ABSTRACT Objective Falls are a leading cause of morbidity and loss of independence in adults. The association between overactive bladder (OAB) and fall risk has not been thoroughly investigated. This study evaluated the association between OAB and fall history in a nationally representative sample of US adults aged 20−69 years. Methods We performed a cross‐sectional analysis of adults aged 20−69 years from the 2021−2023 National Health and Nutrition Examination Survey (NHANES). OAB was classified using a composite symptom severity score that assessed urge urinary incontinence and nocturia. Fall history was assessed by self‐reporting (only in participants aged 20−69 years), where a recent fall was defined as experiencing at least one fall within the past year. Survey multivariable logistic regression was used to estimate adjusted odds ratios (aOR) for the association between fall history and OAB after controlling for sociodemographic and clinical covariates. Results Among 4118 participants, the population‐weighted prevalence of OAB was 19.6% (standard error [SE]: 1.1%), and the prevalence of a recent fall was 28.3% (SE: 1.3%). The prevalence of a recent fall was higher among those with OAB (39.7% [SE: 1.6%] vs. 25.7% [SE: 1.5%]). The prevalence of a recent fall increased progressively with OAB symptom severity (24.3% in those with no symptoms vs. 52.4% in those with severe symptoms). In the fully adjusted model controlling for sociodemographic and clinical covariates, OAB was independently associated with a 42% higher odds of experiencing a recent fall (aOR, 1.42; 95% CI, 1.10 to 1.83; p = 0.01). Conclusion OAB is independently associated with an increased risk of a recent fall in US adults aged 20‐69 years, with a strong positive relationship between OAB severity and fall risk. These findings suggest that screening for OAB may be a useful adjunct to fall risk assessment. Future studies are needed to determine whether OAB management reduces the risk of falls.
Herpesvirus genome integration in whole‐genome sequences of dementia and control cohorts
Piotrowski, Stacey L. , Allnutt, Mary Alice , Johnson, Kory, Ferrucci, Luigi, Morris, Huw, Hardy, John, Ryten, Mina, Logroscino, Giancarlo, Troncoso, Juan C. , Beach, Thomas G., Serrano, Geidy E., Cruchaga, Carlos, Ross, Owen A., Chiò, Adriano, Ding, Jinhui, Scholz, Sonja W. , Jacobson, Steven, Hardy, John , May, Patrick , Scholz, Sonja W , Hardy, John , May, Patrick , Houlden, Henry , Johnson, Kory, Tanaka, Toshiko , Ferrucci, Luigi , Ryten, Mina , Logroscino, Giancarlo , Beach, Thomas G. , Serrano, Geidy E. , Cruchaga, Carlos , Dickson, Dennis W. , Ross, Owen A. , Chiò, Adriano , Houlden, Henry , Dalgard, Clifton L. , Ding, Jinhui , Gibbs, J. Raphael , Traynor, Bryan J. , Jacobson, Steven

Mayo Clinic

Alzheimer's & Dementia | March 19, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71047 | PMID 41853978 Get It

Abstract INTRODUCTION The infectious hypothesis suggests that microbes like herpesviruses may play a role in the pathogenesis of Alzheimer's disease (AD) and other related dementias through methods that may include viral genome integration. The occurrence of herpesvirus genome integration in dementia patients has not been thoroughly characterized. METHODS Over 7500 total whole‐genome sequences from control, frontotemporal dementia/amyotrophic lateral sclerosis spectrum, Lewy body dementia (LBD), multiple system atrophy (MSA), and AD cohorts were screened for the integration of pathogen genomes using the PathSeq computational tool. RESULTS Low PathSeq scores for human herpesvirus 6 (HHV‐6) were consistent with the suspected integration of viral genome segments. The LBD and MSA cohorts had a significantly higher prevalence of this partial HHV‐6 genome integration. DISCUSSION This higher prevalence in both synucleinopathies was not noted in other herpesviruses, suggesting that the integration of HHV‐6 may play a role in a subset of these patients. Highlights Over 7500 whole‐genome sequences from controls and dementia patients were analyzed. Sequences consistent with integrated herpesviruses were identified using PathSeq. Prevalence of partial HHV‐6 integration was higher in synucleinopathies. Herpesviruses genome integration may play a role in subsets of dementia patients.
Training for pediatric cannot intubate cannot oxygenate: surgical airway should replace needle cricothyrotomy
Lehman, Allison M.B., Amstutz, Paul, Moore, Jackson E. , Obersteadt, Christopher, Williams, Dominique, Waxman, Mary J., Blubaugh, Morgan , Parikh, Anaya, Walsh, Timothy R., Bruegger, Daniel E., Malik, Adrienne , Pirotte, Andrew, Johnson, Matthew D. , Obersteadt, Chris, Sood, Shawn , Pirotte, Andrew P.

Mayo Clinic

Frontiers in Disaster and Emergency Medicine | March 17, 2026 | Volume: 4 | Issue: No issue available | Pages: No page available

10.3389/femer.2026.1772381 | PMID 41928873 Get It

Failed pediatric endotracheal intubation, prompting surgical airway management via emergency front of neck access (eFONA), is an intrinsically challenging topic. While rare, all emergency airway providers must be equipped to handle these complex clinical scenarios, both through initial training and maintenance of competency. Needle cricothyrotomy is a commonly taught method in cannot intubate cannot oxygenate (CICO) scenarios for children under age eight. However, needle cricothyrotomy is technically difficult, profoundly rare, and maintaining competency is a challenge. From a multidisciplinary perspective, we examine the utility of continuing to teach needle cricothyrotomy and explore alternatives. This project group suggests that pediatric eFONA training across disciplines should focus on surgical tracheotomy rather than needle cricothyrotomy, with consideration given to specialty-specific human performance factors.
Perceptions of Registered Dietitian Nutritionists (RDNs) on the Use of Artificial Intelligence (AI) in Clinical Nutrition Care: A Cross-Sectional Survey Within a Large U.S. Healthcare System
Johnson, Danelle , Hurt, Ryan T. , Mundi, Manpreet S. , Salonen, Bradley R. , Bonnes, Sara L. , Fokken, Shawn C. , Croghan, Ivana T. , Croghan, Ivana T , Edakkanambeth Varayil, Jithinraj , Mundi, Manpreet S , Johnson, Danelle A , Hurt, Ryan T , Schroeder, Darrell R. , Varayil, Jithinraj Edakkanambeth

Mayo Clinic

Nutrients | March 16, 2026 | Volume: 18 | Issue: 6 | Pages: 934

10.3390/nu18060934 | PMID 41901109 Get It

Background: Artificial intelligence (AI) is increasingly being integrated into healthcare, with applications ranging from predictive analytics to clinical decision support. In clinical nutrition, AI tools offer opportunities to improve workflow efficiency, enhance dietary assessment, and personalize nutrition care. Despite growing interest, little is known about registered dietitian nutritionists’ (RDNs) perceptions of AI in clinical practice. The aim of the present study was to assess RDNs’ attitudes toward AI use within a large healthcare system, along with their perceived barriers in this regard. Methods: A cross-sectional survey was developed through expert review and distributed electronically via REDCap to RDNs across Mayo Clinic’s academic campuses and affiliated health system sites. The 23-item survey included Likert-scale items addressing AI’s potential utilization within clinical care, perceived benefits and risks, and readiness for adoption. Responses were summarized using descriptive statistics. Factor analysis identified underlying constructs related to AI attitudes. Differences stratified by age and years of experience were evaluated using ANOVA. Results: Of the 185 RDNs invited, 64 (35%) responded. Two factors emerged: optimism regarding AI usage (Cronbach’s α = 0.94) and skepticism about implementation (α = 0.76). The overall mean ± SD score for optimism was 0.1 ± 0.6 (neutral), while skepticism averaged 1.0 ± 0.6 (moderate). Skepticism differed by years of experience (p = 0.012), with the lowest levels observed among RDNs with ≥21 years of practice. No significant differences were observed across age groups. Discussion: RDNs demonstrated neutral attitudes toward AI use but expressed concerns about accuracy, training, and implementation challenges. Addressing these concerns through education and structured implementation strategies may facilitate successful adoption of AI in dietetic practice.